CSV February 23, 2023 through February 23, 2025 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ELEMENTAL I	*Drug Substance*	*Second*	5633	31-Jan-2013	1-Feb-2013	*USP37–NF32*	*Second*	Row 16 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
MPURITIES--LIMITS	*and Excipients*	*Supplement to USP35–NF30*					*Supplement to USP36–NF31*	Column 4 of *Table 2*: Change 7 to: 10
VIRAL SAFETY EVALUATION OF BIOTECHNOLOGY PRODUCTS DERIVED FROM CELL LINES OF HUMAN OR ANIMAL ORIGIN	*VI. Evaluation and Characterization of Viral Clearance Procedures*	*USP35–NF30*	553	31-Jan-2013	1-Feb-2013	*USP37–NF32*	*Second Supplement to USP36–NF31*	Row 10 (Reovirus 3) of Column 5 (Genome) of *Table A-1*: Change DNA to: RNA
MYRISTYL ALCOHOL	SPECIFIC TESTS/*Fats and Fixed Oils, Hydroxyl Value <401>*	*USP35–NF30*	1873	31-Jan-2013	1-Feb-2013	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 7 of *Analysis*: Change Result = [(V_U ? V_B) × F]/W V_U = volume of 1 N sodium hydroxide consumed by the *Sample* (mL) V_B = volume of 1 N sodium

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								hydroxide consumed by the *Blank* (mL) to: Result = [(V_B ? V_U) × F]/W V_B = volume of 1 N sodium hydroxide consumed by the *Blank* (mL) V_U = volume of 1 N sodium hydroxide consumed by the *Sample* (mL)
ONDANSETRON INJECTION	*USP Reference Standards*	*USP35–NF30*	4120	31-Jan-2013	1-Feb-2013	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 7: Delete USP Ondansetron Related Compound B RS 6,6´-Methylene bis-[(1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1*H*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-imidazol-1-yl)-methyl]-4*H* -carbazol-4-one .
ZINC GLUCONATE	IM PURITIES/*Limit of Cadmium*	*USP35–NF30*	5070	31-Jan-2013	1-Feb-2013	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 22 of *Analysis*: Change *W* = weight of Calcium Gluconate taken to prepare *Sample solution A* (g) to: *W* = weight of Zinc Gluconate taken to prepare *Sample solution A* (g)
TACROLIMUS ORAL SUSPENSION	ASSAY/ *Chromatographic system*	*USP36–NF31*	5261	31-Jan-2013	1-Feb-2013	*USP37–NF32*	*Second Supplement to USP36–NF31*	After line 1 of *Column*: Add a new section *Column temperature*: 70°
GLYCERYL MONOOLEATE	SPECIFIC TESTS/*Fats and Fixed Oils, Fatty Acid Composition*	*USP35–NF30*	1814	31-Jan-2013	1-Feb-2013	*USP37–NF32*	*Second Supplement to USP36–NF31*	Column 3 of *Table 1*: Change in Row 1 Percentage,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	<401>							NMT (%) to: Percentage (%) Change in Row 2 12.0 to: NMT 12.0 Change in Row 3 6.0 to: NMT 6.0 Change in Row 4 60.0 to: NLT 60.0 Change in Row 5 35.0 to: NMT 35.0 Change in Row 6 2.0 to: NMT 2.0 Change in Row 7 2.0

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: NMT 2.0 Change in Row 8 2.0 to: NMT 2.0
LORATADINE ORALLY-DISINTEGRATING TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards*	*USP35–NF30*	3714	31-Jan-2013	1-Feb-2013	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 4 of *USP Reference Standards*: Change 8-Chloro-6,11-dihydro-11-(4-piperidylidene)-5*H*-benzo[5,6]cyclohepta[1,2-*b*]pyridine. to: 8-Chloro-5,6-dihydro-11-(piperidi *H*-benzo[5,6]cyclohepta[1,2-*b*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								]pyridine. AND Line 6: Change 310.83 to: 310.82 AND Line 8: Change 8-Chloro-6,11-dihydro -11-(*N* -methyl-4-piperidylid ene)-5*H* -benzo[5,6]cyclohe pta[1,2-*b*]pyridine. to: 8-Chloro-5,6-dihydro-1 1-(*N* -methylpiperidin -4 -ylid ene)-11*H* -benzo[5,6]cyclohe pta[1,2-*b*]pyridine. AND

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Line 10: Change 324.88 to: 324.85
TRIAZOLAM TABLETS	*Assay*	*USP35–NF30*	4936	31-Jan-2013	1-Feb-2013	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 2: Change *Mobile phase* and *Chromatographic system* —Proceed as directed in the *Assay* under *Triazolam*. to: *Mobile phase*—Prepare a filtered and degassed mixture of acetonitrile, chloroform, butyl alcohol, water, and glacial acetic acid (850:80:50:20:0.5). Make adjustments if necessary (see *System*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Suitability under *Chromatography* <621>). AND After the *Assay preparation* subsection: Add a new subsection *Chromatographic system* (see *Chromatography* <621>)—The liquid chromatograph is equipped with a 254-nm detector and a 4.6-mm × 30-cm column that contains packing L3. The flow rate is about 2.0 mL per minute. Chromatograph the *Standard preparation*, and record the peak responses as directed

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								under *Procedure*: the relative retention times are 1 for triazolam and about 1.4 for the internal standard, the resolution, *R*, between the internal standard and triazolam is not less than 2.0, and the relative standard deviation for replicate injections is not more than 2.0%. AND Line 4 of *Procedure*: Change Calculate the quantity, in mg, of $C_{17}H_{12}Cl_2N_4$ in the portion of Triazolam taken

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								by the formula: to: Calculate the quantity, in mg, of $C_{17}H_{12}Cl_2N_4$ in the portion of Tablets taken by the formula: AND Line 9 of *Procedure*: Change R_U and R_S are the ratios of the internal standard peak area to the triazolam peak area obtained from the *Assay preparation* and the *Standard preparation*, respectively. to: R_U and R_S are the ratios of the triazolam peak area to the internal standard peak

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								area obtained from the *Assay preparation* and the *Standard preparation*, respectively.
AZITHROMYCIN FOR INJECTION	IMPURITIES/*Limit of Aminoazithromycin, Formamido Analog, Methylformamido Analog, and 3'-De(dimethylamino)-3'-oxoazithromycin (if present)*	*Second Supplement to USP35–NF30*	5910	31-Jan-2013	1-Feb-2013	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 1 of *Buffer*: Change 3.5 g/mL to: 3.5 g/L
Esomeprazole Magnesium Delayed-Release Capsules	ASSAY/*Procedure*	*First Supplement to USP35–NF30*	5473	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 1 of *Standard solution*: Change Transfer 10 mg of USP Omeprazole RS to a 250-mL volumetric flask, and dissolve in about 10 mL of methanol. to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Transfer 10 mg of USP Omeprazole RS to a 250-mL volumetric flask, and dissolve in about 10 mL of alcohol.
Carisoprodol Tablets	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*Second Supplement to USP35–NF30*	5921	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 5: At end of *USP Reference Standards*, add USP Meprobamate RS
Olanzapine Tablets	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*Revision Bulletin (Official July 01, 2012)*	Online	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Lines 3 and 6: Change USP Olanzapine Related Compound A RS 5-Methyl-2-((2-nitrophenyl)amino)-3-thiophenecarbonitrile. USP Olanzapine Related Compound B RS

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								2-Methyl-10*H*-thieno-[2,3-*b*][1,5]benzodiazepin-4[5*H*]-one. to: USP Olanzapine Related Compound A RS 5-Methyl-2-((2-nitrophenyl)amino)-3-thiophenecarbonitrile. $C_{12}H_9N_3O_2S$ 259.28 USP Olanzapine Related Compound B RS 2-Methyl-10*H*-thieno-[2,3-*b*][1,5]benzodiazepin-4[5*H*]-one.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$C_{12}H_{10}N_2OS$ 230.29
Aminosalicylate Sodium	*Limit of m-aminophenol*	*USP35–NF30*	2177	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 1 of *Test preparation*: Change Use the *Assay preparation*, prepared as directed in the *Assay*. to: Transfer about 69 mg of Aminosalicylate Sodium, accurately weighed, to a 100-mL low-actinic volumetric flask, add 50 mL of *Mobile phase*, and swirl to dissolve. Add 10.0 mL of *Internal standard solution*, dilute with *Mobile phase* to volume, and

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								mix.
Dibasic Calcium Phosphate Dihydrate	ASSAY	*USP35–NF30*	2463	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 14 of *Analysis*: Change *W* = *Sample weight* (mg) to: *W* = *Sample weight* (mg) in 20.0 mL of the *Sample solution*
Glimepiride Tablets	PERFORMANCE TESTS/ *Dissolution*/*Test 1*	*USP35–NF30*	3335	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 3 of *Analysis*: Change Result = $(r_U/r_S) \times (C_S/L) \times V \times 100$ to: Result = $(r_U/r_S) \times (C_S/L) \times V \times D$ x 100 AND after Line 8 of *Analysis*: Add *D* = dilution factor of the *Sample solution*
Compound Undecylenic Acid Ointment	*Assay for zinc undecylenate*	*USP35–NF30*	4978	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 17 of *Procedure*: Change *A*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$_U$, A_H, and A_L to: A_U, A_{S1}, and A_{S2}
Itraconazole	IM PUR ITIES/*Organic Impurities*	*First Supplement to USP35–NF30*	5508	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 1 of *Standard solution*: Change 1.0 µg/mL of USP Itraconazole RS in *Diluent* to: 10.0 µg/mL of USP Itraconazole RS in *Diluent*
Olanzapine Tablets	ASSAY/ *Procedure*	*Revision Bulletin (Official July 01, 2012)*	Online	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 10 of *Analysis*: Change C_U = concentration of olanzapine in the *Sample solution* (mg/mL) to: C_U = nominal concentration of olanzapine in the *Sample solution*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(mg/mL)
Polysorbate 80	SPECIFIC TESTS/*Fats and Fixed Oils, Peroxide Value <401>*	*USP35–NF30*	1920	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 5 of *Analysis*: Change 0.01 M sodium thiosulfate to: 0.01 M sodium thiosulfate VS
Ampicillin Sodium	SPECIFIC TESTS/*pH <791>*	*USP35–NF30*	2213	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 2: Change text of *Sample solution* from 10.0 mg/mL to: 10.0 mg/mL of ampicillin
Anhydrous Dibasic Calcium Phosphate	IM PURITIES/*Heavy Metals, Method I <231>*	*USP35–NF30*	2464	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 1 of *Test preparation*: Change Warm 1.3 g with 3 mL of 3 N hydrochloric acid to completely dissolve. to: Warm 1.3 g with 3 mL of 3 N hydrochloric acid until no more dissolves.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
Tramadol Hydrochloride Tablets	IMPURITIES/*Organic Impurities/Procedure*	*USP35–NF30*	4905	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 5 of *Analysis*: Change Result = $(r_U/r_S) \times (C_S/C_U) \times (1/F) \times 0.1$ to: Result = $(r_U/r_S) \times (C_S/C_U) \times (1/F) \times 100$
Esomeprazole Magnesium Delayed-Release Capsules	PERFORMANCE TESTS/ *Dissolution <711>*	*First Supplement to USP35–NF30*	5473	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Change *Buffer, Diluent, Mobile phase, System suitability, and Chromatographic system*: Proceed as directed in the *Assay*. to: *Buffer*, *Mobile phase*, *System suitability, and Chromatographic system*: Proceed as directed in the *Assay.*
Cefepime Hydrochloride	IMPUR	*Second Supplement to*	5923	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to*	Line 5 of *Chromatographi*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	ITIES/*Organic Impurities/Procedure 1: Limit of N-Methylpyrrolidine*	*USP35–NF30*					*USP36–NF31*	*c system*: Change *Column:* 4.0-mm x 25-cm; 5-µm packing L##[1] to: *Column:* 4.0-mm x 25-cm; 5-µm packing L76 AND Delete corresponding footnote: "Available as Metrosep C4-250."
Antibiotics—Microbial Assays	*Turbidimetric Method*	*USP35–NF30*	74	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 8 of *Analysis*: Change Include in each rack 1–2 control tubes containing 1 mL of the inoculum medium (see *Table 8*) but no antibiotic. to: Include in each

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								rack 1–2 control tubes containing 1 mL of the test diluent (see *Table 7*) but no antibiotic.
Aminosalicylate Sodium Tablets	*Limit of m-aminophenol*	*USP35–NF30*	2178	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 1 of *Test solution*: Change Use the *Assay preparation*, prepared as directed in the *Assay*. to: Weigh and finely powder not fewer than 20 Tablets. Transfer an accurately weighed portion of the powder, equivalent to about 690 mg of aminosalicylate sodium, to a 100-mL low-actinic volumetric flask.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Add 50 mL of *Mobile phase*, and shake for about 5 minutes. Dilute with *Mobile phase* to volume, and mix. Filter, and transfer 10.0 mL of the clear filtrate to a low-actinic, 100-mL volumetric flask containing 10.0 mL of *Internal standard solution*, dilute with *Mobile phase* to volume, and mix.
Dibasic Calcium Phosphate Dihydrate	IMPURITIES/*Heavy Metals, Method I <231>*	*USP35–NF30*	2463	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 1 of *Test preparation*: Change Warm 1.3 g with 3 mL of 3 N hydrochloric acid to completely dissolve.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: Warm 1.3 g with 3 mL of 3 N hydrochloric acid until no more dissolves.
Moxifloxacin Ophthalmic Solution	*Related compounds/Test 1*	*USP35–NF30*	3960	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 4 of *Chromatographic system*: Delete The flow rate is about 0.5 mL per minute.
Containers—Glass	SPECIFIC TESTS/ *Hydrolytic Resistance/Method*	*First Supplement to USP35–NF30*	5150	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	In the Note in line 11 of *Titration*: Change Rinse the grains by swirling with three 15-mL portions of Purified Water, and add the washings to the main solution. to: Rinse the grains by swirling with three 15-mL portions of Carbon Dioxide-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Free Water, and add the washings to the main solution.
Omega-3-Acid Ethyl Esters Capsules	SPECIFIC TESTS/ *Microbial Enumeration <61>*	*First Supplement to USP35–NF30*	5524	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*First Supplement to USP36–NF31*	Line 2: Change 10^3 to: 10^3 cfu/g AND Line 3: Change 10^2 to: 10^2 cfu/g
Olanzapine Tablets	IM PUR ITIES/*Organic Impurities*	*Revision Bulletin (Official July 01, 2012)*	Online	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 11 of *Analysis*: Change C_U = concentration of olanzapine in the *Sample solution* (mg/mL) to: C_U = nominal concentration of olanzapine in the *Sample solution* (mg/mL)
Polysorbate 80	SPECIFIC TESTS/*Fats*	*USP35–NF30*	1920	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to*	Line 3 of *Analysis*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	and Fixed Oils, Saponification Value <401>						*USP36–NF31*	Change 0.5 N alcoholic potassium hydroxide to: 0.5 N alcoholic potassium hydroxide VS Line 6 of *Analysis*: Change 0.5 N hydrochloric acid to: 0.5 N hydrochloric acid VS
Budesonide	ASSAY/ *Procedure*	*USP35–NF30*	2394	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 2 of *Acceptance criteria*: Change *Epimer A:* 40.0%–51.0% on the dried basis to: *Epimer A:* 40.0%–51.0%
Cod Liver Oil	ASSAY/*Vitamin D*	*USP35–NF30*	2756	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to*	Line 1 of *Aqueous*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							USP36–NF31	*potassium hydroxide solution*: Change Dissolve 800 mg of potassium hydroxide in 1000 mL of freshly boiled water, mix, and cool. to: Dissolve 800 g of potassium hydroxide in 1000 mL of freshly boiled water, mix, and cool.
Triclosan	*Related compounds*	*USP35–NF30*	4939	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 1 of *Procedure*: Change Inject a volume (about 0.5 µL) to: Inject a volume (about 2.0 µL)
Esterified Estrogens Tablets	ASSAY/ *Procedure*	*First Supplement to USP35–NF30*	5485	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 3 of *Analysis*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
Cefepime for Injection	IM PURITIES/*Organic Impurities/Procedure 1: Limit of N-Me*	*Second Supplement to USP35–NF30*	5925	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Separately calculate the percentage of the labeled amount of sodium estrone sulfate and sodium equilin sulfate in the portion of Conjugated Estrogens taken: to: Separately calculate the percentage of the labeled amount of sodium estrone sulfate and sodium equilin sulfate in the portion of Tablets taken: Line 5 of *Chromatographic system*: Change *Column:* 4.0-mm x

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	thylpyrrolidine							25-cm; 5-µm packing L##[1] to: *Column:* 4.0-mm x 25-cm; 5-µm packing L76 AND Delete corresponding footnote: Available as Metrosep C4-250.
Polysorbate 80	SPECIFIC TESTS/*Fats and Fixed Oils, Hydroxyl Value <401>*	*USP35–NF30*	1920	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 13 of *Analysis*: Change 0.5 N alcoholic potassium hydroxide to: 0.5 N alcoholic potassium hydroxide VS
Aminosalicylic Acid Tablets	*Limit of m-aminophenol*	*USP35–NF30*	2179	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Change the subsection: *Mobile phase* and *Internal standard solution* —Prepare as

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								directed in the *Assay* under *Aminosalicylic Acid*. to: *Mobile phase*—Prepare as directed in the *Assay* under *Aminosalicylic Acid*. *Internal standard solution*—Prepare a solution of sulfanilamide in *Mobile phase* having a concentration of about 5 µg per mL. Line 1 of *Test solution*: Change Use the *Assay preparation*, prepared as directed in the *Assay*.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: Weigh and finely powder not fewer than 20 Tablets. Transfer an accurately weighed portion of the powder, equivalent to about 500 mg of aminosalicylic acid, to a 100-mL low-actinic volumetric flask. Add 50 mL of *Mobile phase*, and shake for about 5 minutes. Dilute with *Mobile phase* to volume, and mix. Filter, and transfer 10.0 mL of the clear filtrate to a 100-mL low-actinic volumetric flask

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								containing 10.0 mL of *Internal standard solution*, dilute with *Mobile phase* to volume, and mix.
Anhydrous Dibasic Calcium Phosphate	ASSAY	*USP35–NF30*	2464	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	In line 14 of *Analysis*: Change *W* = *Sample* weight (mg) to: *W* = *Sample* weight (mg) in 20.0 mL of the *Sample solution*
Metronidazole	ASSAY	*USP36–NF31*	4352	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 8 of *Chromatogaphic system*: Add new subsection after *Injection volume*: *Run time:* Twice the retention time of metronidazole
DESCRIPTION AND SOLUBILITY	*Ethylcellulose Dispersion Type B*	*USP35–NF30*	1118	28-Sep-2012	1-Oct-2012	*USP37–NF32*	*First Supplement to USP36–NF31*	Lines 3 and 4: Change in toluene, in

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								chloroform, and in ethyl acetate; insoluble in water, in glycerin, and in propylene glycol. to: in tetrahydrofuran, and in ethyl acetate; insoluble in water and in chloroform.
DELIVERABLE VOLUME	ACCEPTANCE CRITERIA/*For Multiple-Unit Containers*	*First Supplement to USP35–NF30*	5154	28-Sep-2012	1-Oct-2012	*USP37–NF32*	*First Supplement to USP36–NF31*	*Figure 1*, right branch, left box: Change Volume of 1 more containers is less than 95% LV to: Volume of 1 or more containers is less than 95% LV
MAGNESIUM STEARATE	IMPURITIES/*Chloride and Sulfate,*	*USP35–NF30*	1847	28-Sep-2012	1-Oct-2012	*USP37–NF32*	*First Supplement to USP36–NF31*	Line 3: Change 0.020 N sulfuric acid (1.0%) to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Sulfate <221>							0.020 M sulfuric acid (1.0%)
TACROLIMUS	IM PUR ITIES/ *Procedure 2*	*First Supplement to USP35–NF30*	5538	28-Sep-2012	1-Oct-2012	*USP37–NF32*	*First Supplement to USP36–NF31*	Footnote h of *Table 3*: Change (3*S*,4*R*,5*S*,8*S*,9*E*,12*S*,14*S*,15*R*,16*S*,18*R*,19*R*,26a*S*)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-{(*E*)-2-[(1*R*,3*R*,4*R*)-4-hydroxy-3-methoxycyclohexyl]-1-methylvinyl}-14,16-dimethoxy-4,10,12,18-tetramethyl-15,19-epoxy-8-propyl-3*H*-pyrido[2,1-*c*][1,4]oxaazacyclotricosine-1,7,20,21(4*H*,23*H*)-tetrone.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: (3*S*,4*R*,5*S*,8*R*,9*E*,12*S*,14*S*,15*R*,16*S*,18*R*,19*R*,26a*S*)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-{(*E*)-2-[(1*R*,3*R*,4*R*)-4-hydroxy-3-methoxycyclohexyl]-1-methylvinyl}-14,16-dimethoxy-4,10,12,18-tetramethyl-15,19-epoxy-8-propyl-3*H*-pyrido[2,1-*c*][1,4]oxaazacyclotricosine-1,7,20,21(4*H*,23*H*)-tetrone.
SODIUM HYDROXIDE	ASSAY/ *Procedure*	*USP35–NF30*	1955	28-Sep-2012	1-Oct-2012	*USP37–NF32*	*First Supplement to USP36–NF31*	Line 10 of *Analysis*: Change Result = {[(*V*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$_{S1}$? V_B) × N × F_1]/W} × 100 to: Result = {[(V_{S2} ? V_B) × N × F_1]/W} × 100 AND Line 11 of *Analysis*: Change V_{S1} to: V_{S2}
ELEMENTAL IMPURITIES—LIMITS	DRUG PRODUCTS/*Large Volume Parenterals*	*Second Supplement to USP35–NF30*	5633	28-Sep-2012	1-Oct-2012	*USP37–NF32*	*First Supplement to USP36–NF31*	Row 13 of *Column 4* of *Table 1*: Change 250 to: 10
ALPRAZOLAM ORALLY-DISINTEGRATING TABLETS	IMPURITIES/ *Procedure*	*USP35–NF30*	2106	28-Sep-2012	1-Oct-2012	*USP37–NF32*	*First Supplement to USP36–NF31*	Change the subsection *Buffer* and *Diluent*: Prepare as directed in the *Assay*. to: *Diluent*: Prepare as directed in the *Assay*.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Buffer: 6.8 g/L of monobasic potassium phosphate in water. Adjust with phosphoric acid to a pH of 3.0.
INDINAVIR SULFATE	OTHER COMPONENTS/*Procedure 2: Content of Alcohol*	*USP35–NF30*	3489	28-Sep-2012	1-Oct-2012	*USP37–NF32*	*First Supplement to USP36–NF31*	Line 6 of *Chromatographic system* in the subsection *Column*: Change G14 to: G16

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 32
- Page 33
- Page 34
- Page 35
- Page 36
- Page 37
- Page 38
- Page 39